22.05.2014 Celesio AG  DE000CLS1001

DGAP-News: Celesio AG: Changes in management of Celesio AG


 
DGAP-News: Celesio AG / Key word(s): Change of Personnel Celesio AG: Changes in management of Celesio AG 22.05.2014 / 13:29 --------------------------------------------------------------------- Changes in management of Celesio AG Stuttgart, 22 May 2014. The Supervisory Board of Celesio AG today appointed Marc Owen, to date President of McKesson Specialty Health and member of the McKesson Operating Team, and Alain Vachon, to date Senior Vice President and Chief Financial Officer of McKesson U.S. Pharmaceutical, as new members of the Management Board of Celesio AG with effect from 16 July 2014. Marc Owen will take over the position of Chairman of the Management Board and Alain Vachon will take over the position of Chief Financial Officer. The current speaker of the Management Board and Chief Financial Officer Dr. Marion Helmes has by mutual agreement with the Supervisory Board resigned from her office and terminated her engagement with the Company with effect as of the end of 15 July 2014. The Chief Operating Officer Martin Fisher has by mutual agreement with the Supervisory Board also resigned from his office with effect as of the end of 22 May 2014. Dr. Marion Helmes will additionally take over the position of interim Chief Operating Officer until and including 15 July 2014. The Management Board and the Supervisory Board of Celesio AG today further resolved to enter into the domination and profit and loss transfer agreement with Dragonfly GmbH & Co. KGaA, a 100% indirect subsidiary of McKesson Corporation in line with the terms previously announced (see also ad hoc announcement of Celesio AG of 14 May 2014). The Agreement is expected to be executed by both parties today and will be presented to the Annual General Meeting of Celesio AG for approval on 15 July 2014. Contacts Celesio Group Investor Relations: Markus Georgi, +49 (0)711.5001-1208 [email protected] Michael Otto, +49 (0)711.5001-635 [email protected] Media: Marc Binder, +49 (0)711.5001-380 [email protected] Rainer Berghausen, +49 (0)711.5001-549 [email protected] About Celesio Group Celesio is a leading international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors. The proactive and preventive approach ensures that patients receive the products and support that they require for optimum care. With some 39,000 employees, Celesio operates in 14 countries around the world. Every day, the group serves over 2 million customers - at 2,200 pharmacies of its own and 4,200 participants in brand partnership schemes. With approximately 130 wholesale branches, Celesio supplies 65,000 pharmacies and hospitals every day with up to 130,000 pharmaceutical products. The services benefit a patient pool of about 15 million per day. End of Corporate News --------------------------------------------------------------------- 22.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Celesio AG Neckartalstr. 155 70376 Stuttgart Germany Phone: +49 (0)711 5001-735 Fax: +49 (0)711 5001-740 E-mail: [email protected] Internet: www.celesio.com ISIN: DE000CLS1001, DE000CLS1043 WKN: CLS100, CLS104 Indices: MDAX Listed: Regulierter Markt in Berlin, Düsseldorf, Frankfurt (Prime Standard), München, Stuttgart; Freiverkehr in Hamburg, Hannover; Terminbörse EUREX End of News DGAP News-Service --------------------------------------------------------------------- 270044 22.05.2014


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 21.090,00 20.643,70 21.090,00 16.416,80 8.517,70 9.257,10 0,00
EBITDA1,2 147,50 393,90 147,50 137,10 126,30 113,50 0,00
EBITDA-Marge3 0,70 1,91 0,70 0,84 1,48 1,23 0,00
EBIT1,4 -284,60 -699,40 -284,60 2,70 -12,50 -46,30 0,00
EBIT-Marge5 -1,35 -3,39 -1,35 0,02 -0,15 -0,50 0,00
Jahresüberschuss1 -299,00 -966,00 -295,30 -54,60 -7,30 -867,40 0,00
Netto-Marge6 -1,42 -4,68 -1,40 -0,33 -0,09 -9,37 0,00
Cashflow1,7 265,90 422,30 265,90 345,00 362,50 0,90 0,00
Ergebnis je Aktie8 -1,49 -3,97 -1,47 -0,29 -1,22 -4,29 0,64
Dividende8 0,83 0,83 0,83 0,83 0,83 0,83 0,83
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
McKesson Europe
WKN Kurs in € Einschätzung Börsenwert in Mio. €
CLS100 20,700 Halten 4.206,67
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
25,88 22,33 1,16 -24,38
KBV KCV KUV EV/EBITDA
1,69 4.674,08 0,45 20,95
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,83 0,83 4,01 29.07.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.06.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
1,71% -4,56% -13,75% -12,29%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Celesio AG  ISIN: DE000CLS1001 können Sie bei EQS abrufen


Handel , CLS100 , CLS1 , SWB:​MCK